TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4, a larger peptide found throughout the body.

Is TB-500 the same as thymosin beta-4?

No, TB-500 is a 7-amino-acid synthetic fragment of the 43-amino-acid full-length thymosin beta-4.

What is TB-500 commonly researched for?

TB-500 is most often referenced in research-use contexts focused on actin-mediated cell migration and tissue repair signaling.

What is a typical TB-500 dosing pattern in research planning?

Community-referenced research planning frequently uses about 2 to 2.5 mg subcutaneous twice weekly during a 4-6 week loading phase.

How is TB-500 reconstituted?

Most planners reconstitute a 10 mg vial with 2.0 mL of bacteriostatic water, which gives 5 mg/mL.

How long is a typical TB-500 cycle?

Common research-use cycles run 4-12 weeks, typically with a 4-6 week loading phase followed by maintenance.

Can BPC-157 and TB-500 be used together?

Yes, the BPC-157 + TB-500 combination is commonly paired in the research-use community.

Is TB-500 FDA-approved?

No, TB-500 is not approved by the FDA for any human use.

Peptidesubcutaneous

TB-500 / TB4

TB-500 (thymosin beta-4 fragment) is a 17-amino-acid synthetic peptide derived from the active region of thymosin beta-4. Studied in cellular-repair and angiogenesis research models.

Extreme close-up of pale crystalline material, light scattering through it

Researched for

Tissue RepairSoft Tissue RecoveryTendon/Ligament RecoveryInjury RecoveryPerformance RecoveryRecovery

Not yet audited

We have not published an audit on TB-500 / TB4. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.

How it is thought to work

Actin regulation; potential cell migration and repair signaling.

TB-500 is a small synthetic piece of a naturally occurring protein called thymosin beta-4; it keeps the part of that protein that binds to actin and may support tissue repair and new blood vessel formation, but most of the supporting research was done on the full-length protein, not this fragment.

Reported side effects

The most commonly reported effects in the research-use community are mild injection-site discomfort, redness, and brief fatigue or head-pressure in the first few days, while theoretical concerns include unwanted angiogenesis and immune modulation that have not been studied in humans.

What sources report

Reference, not a recommendation

These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for TB-500 / TB4 or for anything else, and nothing below has been checked against the study it came from.

Amount	Frequency	Route	Reported by
Standard: 2-2.5 mg subcutaneous twice weekly · Low: 2 mg twice weekly · High: 2.5 mg subcutaneous once weekly	twice weekly for loading, once weekly for maintenanceWeeks 1-6 for loading, Weeks 7-12 for maintenance · 4-12 weeks	subcutaneous injection	Peptide Dosing Protocols What it saysHide (secondary reference; provider confirmation required). TB-500 is commonly dosed at 2-2.5 mg subcutaneously twice weekly during the loading phase.
2-2.5 mg SC twice weekly (loading 4-6 weeks), then 2 mg weekly maintenance	twice weekly (loading), then weekly4-6 week loading, then maintenance · Loading phase then maintenance phase	subcutaneous	Commonly published practitioner dosing range - provider confirmation required.
2-2.5 mg per injection (loading); 750 mcg-2 mg (maintenance)	not stated	subcutaneous or oral or topical	Peptide Protocol Wiki What it saysHide (secondary reference; provider confirmation required).
Referenced with a loading phase of 5-10 mg weekly for 4-6 weeks, then maintenance at 2-5 mg weekly split into smaller doses. Results typically noticed within 2-4 weeks. Caution flag: angiogenesis-promoting, so cancer or tumor history warrants medical consultation first.	Weekly total (2-10 mg) split into smaller doses · Post-workout or before bedOn-cycle 4-6 weeks, off-cycle 1-2 months	subcutaneous or intramuscular	Peptide Therapy Reference Text, internal KB v4 What it saysHide (Aug 2026), secondary reference; provider confirmation required.

Standard: 2-2.5 mg subcutaneous twice weekly · Low: 2 mg twice weekly · High: 2.5 mg subcutaneous once weekly

Frequency: twice weekly for loading, once weekly for maintenanceWeeks 1-6 for loading, Weeks 7-12 for maintenance · 4-12 weeks
Route: subcutaneous injection
Reported by: Peptide Dosing Protocols
What it saysHide
(secondary reference; provider confirmation required). TB-500 is commonly dosed at 2-2.5 mg subcutaneously twice weekly during the loading phase.

2-2.5 mg SC twice weekly (loading 4-6 weeks), then 2 mg weekly maintenance

Frequency: twice weekly (loading), then weekly4-6 week loading, then maintenance · Loading phase then maintenance phase
Route: subcutaneous
Reported by: Commonly published practitioner dosing range - provider confirmation required.

2-2.5 mg per injection (loading); 750 mcg-2 mg (maintenance)

Frequency: not stated
Route

Reconstitution, as reported

2.0 mL bacteriostatic water for 10 mg vial
Commonly 5 mg or 10 mg vials · Reconstitute with bacteriostatic water
Bacteriostatic water

TB-500 / TB4

How it is thought to work

Reported side effects

Who should avoid it

What gets monitored